Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 17

1.

Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients.

Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M.

J Nucl Med. 2005 Aug;46(8):1333-41.

2.

Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.

Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M.

PLoS Med. 2005 Mar;2(3):e70. Epub 2005 Mar 29.

3.

Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD.

Pichler BJ, Kneilling M, Haubner R, Braumüller H, Schwaiger M, Röcken M, Weber WA.

J Nucl Med. 2005 Jan;46(1):184-9.

4.

Imaging of angiogenesis.

Sinusas AJ.

J Nucl Cardiol. 2004 Sep-Oct;11(5):617-33. Review. No abstract available.

PMID:
15472646
5.

Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo.

Sadeghi MM, Krassilnikova S, Zhang J, Gharaei AA, Fassaei HR, Esmailzadeh L, Kooshkabadi A, Edwards S, Yalamanchili P, Harris TD, Sinusas AJ, Zaret BL, Bender JR.

Circulation. 2004 Jul 6;110(1):84-90. Epub 2004 Jun 21.

6.

Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies.

Haubner R, Wester HJ.

Curr Pharm Des. 2004;10(13):1439-55. Review.

PMID:
15134568
7.

Integrins: roles in cancer development and as treatment targets.

Jin H, Varner J.

Br J Cancer. 2004 Feb 9;90(3):561-5. Review.

8.

[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates.

Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, Schwaiger M.

Bioconjug Chem. 2004 Jan-Feb;15(1):61-9.

PMID:
14733584
9.

Alpha(v)beta(3) integrin in angiogenesis and restenosis.

Kerr JS, Mousa SA, Slee AM.

Drug News Perspect. 2001 Apr;14(3):143-50.

PMID:
12819820
10.

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.

Kumar CC.

Curr Drug Targets. 2003 Feb;4(2):123-31. Review.

PMID:
12558065
11.

alphav Vitronectin receptors in vascular-mediated disorders.

Mousa SA.

Med Res Rev. 2003 Mar;23(2):190-9. Review.

PMID:
12500288
12.
13.
14.

Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography.

Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M.

Cancer Res. 2001 Mar 1;61(5):1781-5.

15.

Integrins and bone--cell adhesion and beyond.

Grzesik WJ.

Arch Immunol Ther Exp (Warsz). 1997;45(4):271-5. Review.

PMID:
9523000
16.

Tumor angiogenesis and the role of vascular cell integrin alphavbeta3.

Varner JA, Cheresh DA.

Important Adv Oncol. 1996:69-87. Review.

PMID:
8791129
17.

Integrins: versatility, modulation, and signaling in cell adhesion.

Hynes RO.

Cell. 1992 Apr 3;69(1):11-25. Review. No abstract available.

PMID:
1555235

Supplemental Content

Support Center